Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia in active rheumatoid arthritis (REALISTIC)
NCT00717236Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2008
- Primary completion
- Mar 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Jul 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00717236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00717236.